## **Electronic Supplementary Information**

## **Analytical Methods**

## Improved strategies for selection and characterization of new monoclonal anti-carbamazepine antibodies during the screening process using feces and fluorescence polarization immunoassay

Lidia Oberleitner,<sup>a,b</sup> Ursula Dahmen-Levison,<sup>c</sup> Leif-Alexander Garbe,<sup>b</sup> Rudolf J. Schneider<sup>a</sup>\*

<sup>a</sup> Bundesanstalt für Materialforschung und –prüfung (BAM), 12205 Berlin, Germany
<sup>b</sup> Institute of Bioanalytics, Department of Biotechnology, Technische Universität
Berlin, 13353 Berlin, Germany

<sup>c</sup> aokin AG, Robert-Rössle-Str. 10, 13125 Berlin, Germany

\* Corresponding author: E-mail: rudolf.schneider@bam.de; Tel: +49 30 8104 1151 Fax: +49 30 8104 71151



Fig. S1: Degrees of polarization (a) and total fluorescence intensities (b) were measured with FPIA depending on the amount of the different purified antibodies added in CBZ FPIA (clone 1-5).



Fig. S2: CBZ FPIA calibration curves for purified antibodies from clone 1, 3 and 4 measured on MTPs after 10 min incubation time (measurements for each calibration point were performed in triplicate).